Gavreto Pralsetinib RET Inhibitor Clinical Review 2026
Author: Critical Kare PharmaMolecular Oncology Desk
On October 22, 2026, thoracic and endocrine oncology consortiums highlighted Gavreto® (Pralsetinib 100 mg capsules) by Blueprint Medicines / Genentech as a potent, once-daily RET kinase inhibitor for RET-altered NSCLC and thyroid cancers.
Gavreto selectively targets oncogenic RET fusions and mutations—including gatekeeper mutations like RET V804L/M that confer resistance to multi-kinase inhibitors—sparing off-target VEGFR2 to minimize vascular hypertension toxicities.
Through Critical Kare Pharma, verified original manufacturer supplies of Gavreto Pralsetinib 100mg Capsules are delivered globally via GDP-compliant logistics.
The ARROW Trial Benchmarks
- High Response Rates: 72% overall response rate in treatment-naive RET fusion-positive NSCLC and 59% in previously treated patients.
- Thyroid Cancer Efficacy: 56% ORR in RET-mutant advanced medullary thyroid cancer.
- Dosing: Recommended starting dose is 400 mg orally once daily on an empty stomach (1 hour before or 2 hours after a meal).
International Supply Sourcing
Managed through verified regulatory import pathways across North America, Europe, and the Middle East via Critical Kare Pharma.
